GlobeNewswire Inc | Oct 26, 2020 08:01AM EDT

October 26, 2020

EMERYVILLE, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2020 and host a corporate update conference call and webcast after the market close on Tuesday, November 10, 2020, at 4:30 PM Eastern Time.

Conference Call DetailsTuesday, November 10, at 4:30 PM Eastern Time / 1:30 PM Pacific TimeToll Free: 877-407-9716International: 201-493-6779Conference ID: 13711927Webcast: http://public.viavid.com/index.php?id= 141969

AboutZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The companys first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.

ZogenixMelinda BakerSenior Director, Corporate Communications+1 (510) 788-8732 |corpcomms@zogenix.com

InvestorsBrian RitchieManaging Director,LifeSci Advisors LLC+1 (212) 915-2578 |britchie@lifesciadvisors.com

MediaIn Europe Kerry Lloyd-Jones, Account Director, Porter Novelli+44 (0) 7949 794 290 | kerry.lloyd-jones@porternovelli.co.ukIn the US Stefanie Tuck, Vice President, Porter Novelli+1 (978) 390-1394 | stefanie.tuck@porternovelli.com